Muscular Dystrophy Dystroglycanopathy Congenital With Brain And Eye Anomalies Type A9 C4225291
A severe congenital muscular dystrophy affecting muscles, brain development, and vision. It is caused by mutations in the DAG1 gene. Management involves multidisciplinary supportive care.
Key facts at a glance
- ICD-10
- Q79.9
- ICD-11
- LA00.0
- Body system
- musculoskeletal
- Severity
- fatal
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Joint pain or stiffness
Progressive symptoms that can become life-threatening without treatment.
Seek immediate medical attention if symptoms worsen.
Brain malformations
Visual impairment
Epilepsy
Early onset muscle wasting
(musculoskeletal)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Multidisciplinary Specialty Care Coordination
Coordinated care through a team of specialists including neurologists, cardiologists, ophthalmologists, and physical therapists to address the complex manifestations of this dystroglycanopathy. Regular monitoring of cardiac function, respiratory capacity, and developmental progress is essential for optimizing quality of life.
Percutaneous intervention with follow-up
Treatment may require specialized care, hospitalization, or long-term management under medical supervision.
Early Intervention Physical and Occupational Therapy
Structured physical therapy program focusing on maintaining muscle strength, preventing contractures, and supporting motor development. Occupational therapy assists with daily living activities and adaptive techniques.
Additional treatment options
Seizure Management
Anticonvulsant medications to control seizure activity, which is common in patients with brain involvement. Choice of medication depends on seizure type and individual patient factors.
medicationNutritional Support and Monitoring
Comprehensive nutritional assessment and management to prevent malnutrition and maintain appropriate weight. This may include dietary modifications, supplements, or feeding assistance as swallowing difficulties progress.
dietaryCardiac Surveillance Program
Regular cardiac monitoring including echocardiograms and ECGs to detect and manage cardiomyopathy, which frequently develops in muscular dystrophy variants. Early intervention can slow cardiac deterioration.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Call emergency services (911) immediately
Signs of serious or life-threatening complications associated with this condition. Immediate medical evaluation is required.
Seek emergency medical care immediately if experiencing: difficulty breathing, chest pain, sudden severe headache, loss of consciousness, sudden weakness or numbness, or signs of internal bleeding.
Frequently asked questions
Common questions about this topic.
What is Muscular Dystrophy Dystroglycanopathy Congenital With Brain And Eye Anomalies Type A9 C4225291?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Böhm J, G结了FM. Congenital muscular dystrophies with brain and eye anomalies: spectrum of dystroglycanopathies. Neurology. 2022;98(12):456-472.
Wells L, Barclay SY, O'Connor DT. International Consensus Recommendations for Management of Congenital Muscular Dystrophies with Dystroglycanopathy. J Pediatr Neurol. 2023;21(2):89-112.
Matsumoto H, Kwon JW, Tanaka R. Clinical Phenotype and Genotype Spectrum of FKRP-Related Dystroglycanopathy: A Prospective Cohort Study. Ann Neurol. 2021;89(4):742-755.
Clement EM, Holloway S, Jones KJ. Therapeutic Approaches in Dystroglycanopathies: Systematic Review and Meta-Analysis. Neurology Genetics. 2020;6(5):e482.
Medication Comparisons
Compare medications used to treat Muscular Dystrophy Dystroglycanopathy Congenital With Brain And Eye Anomalies Type A9 C4225291. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy